Marissa Cole 
A dual GLP-1/GIP receptor agonist made by a Chinese biotech produced up to 18.3% weight loss over 24 weeks in a placebo-controlled phase 2 trial, according to results published on 17 September in Diabetes, Obesity and Metabolism. The drug, BGM0504, acts on the same two gut-hormone receptors as tirzepatide. The trial was small, at 120 … Read more
One of the open questions about GLP-1 drugs is whether they are a good idea in people who are already frail — older, carrying several conditions, less able to absorb a period of appetite loss. A new analysis of the SELECT trial, published in JAMA Cardiology on 16 September 2026, sorted all 17,604 participants by … Read more
If you take a GLP-1 drug and have an operation booked, this is the study to know about. Across 119 UK hospitals and 47,039 patients, regurgitation or stomach contents entering the lungs happened to about 1 in 71 people taking a GLP-1 drug, against about 1 in 802 of everyone else. The events clustered at … Read more
Eli Lilly posted the full results of ACHIEVE-3 to ClinicalTrials.gov on 15 September 2026, and they are the first detailed head-to-head numbers between the two oral GLP-1 drugs. Over 52 weeks in 1,698 adults with type 2 diabetes, the higher dose of orforglipron lowered blood sugar further than the higher dose of oral semaglutide and … Read more
Adolescents with obesity who started semaglutide, liraglutide or tirzepatide were less likely to have a recorded suicide-related event over up to three years than matched adolescents managed with lifestyle intervention, according to an electronic health records study published on 14 September in Diabetes, Obesity and Metabolism. It points away from psychiatric harm in the age … Read more
The European Association for the Study of Obesity has published a position statement whose argument is not about whether incretin drugs work. It treats that as settled. The argument is that everything around the prescription has failed to keep pace: patient selection, monitoring, clinician training and access have all moved more slowly than the drugs, … Read more
Between January 2021 and December 2025, Europe’s pharmacovigilance database logged 42,941 adverse-event reports naming liraglutide, semaglutide or tirzepatide as a suspect drug in diabetes or weight management. Of those, 225 involved suicide or self-injury: 141 for semaglutide, 47 for tirzepatide, 37 for liraglutide. A new analysis sets the three against each other and finds such … Read more
A meta-analysis of 32 randomised trials covering 40,408 people puts the average weight loss on GLP-1 and dual-agonist drugs at 9.36%. Most of the paper is about why that average hides so much. Trials enrolling people who also had type 2 diabetes, obstructive sleep apnoea or fatty liver disease reported systematically smaller losses. Trials that … Read more